OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas

BACKGROUND: In preclinical studies we have defined IDH1R132H as a clonal neoantigen presented on MHC class II. A peptide vaccine encompassing IDH1R132H induces tumor-specific T helper cell responses effective in controlling syngeneic IDH1R132H-mutant tumors in humanized mouse models. MATERIAL AND ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Platten, M, Schilling, D, Bunse, L, Wick, A, Bunse, T, Riehl, D, Green, E, Sanghvi, K, Karapanagiotou-Schenkel, I, Harting, I, Sahm, F, Steinbach, J, Weyerbrock, A, Hense, J, Misch, M, Krex, D, Setvanovic, S, Tabatabai, G, von Deimling, A, Schmitt, M, Wick, W
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Oral Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144380/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.041
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars